BR112013013390A2 - aumento da biodisposnibilidade da droga em uma terapia de naltrexona - Google Patents

aumento da biodisposnibilidade da droga em uma terapia de naltrexona

Info

Publication number
BR112013013390A2
BR112013013390A2 BR112013013390A BR112013013390A BR112013013390A2 BR 112013013390 A2 BR112013013390 A2 BR 112013013390A2 BR 112013013390 A BR112013013390 A BR 112013013390A BR 112013013390 A BR112013013390 A BR 112013013390A BR 112013013390 A2 BR112013013390 A2 BR 112013013390A2
Authority
BR
Brazil
Prior art keywords
drug bioavailability
increased drug
naltrexone therapy
naltrexone
therapy
Prior art date
Application number
BR112013013390A
Other languages
English (en)
Inventor
Eduardo Dunayevich
Shawn Flanagan
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013013390(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of BR112013013390A2 publication Critical patent/BR112013013390A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acoustics & Sound (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
BR112013013390A 2010-12-03 2011-12-02 aumento da biodisposnibilidade da droga em uma terapia de naltrexona BR112013013390A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
PCT/US2011/063177 WO2012075459A1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy

Publications (1)

Publication Number Publication Date
BR112013013390A2 true BR112013013390A2 (pt) 2016-09-06

Family

ID=46172304

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013390A BR112013013390A2 (pt) 2010-12-03 2011-12-02 aumento da biodisposnibilidade da droga em uma terapia de naltrexona

Country Status (26)

Country Link
US (1) US20130245056A1 (pt)
EP (4) EP3884947B1 (pt)
JP (5) JP6008866B2 (pt)
KR (5) KR102105857B1 (pt)
CN (1) CN103313711A (pt)
AR (2) AR093182A1 (pt)
AU (2) AU2011336304B2 (pt)
BR (1) BR112013013390A2 (pt)
CA (2) CA2819262C (pt)
CL (1) CL2013001564A1 (pt)
CY (2) CY1118968T1 (pt)
DK (3) DK3222280T3 (pt)
ES (2) ES2625527T3 (pt)
FI (1) FI3884947T3 (pt)
HR (3) HRP20240115T1 (pt)
HU (2) HUE034393T2 (pt)
IL (3) IL226504B (pt)
LT (3) LT3222280T (pt)
MX (1) MX356801B (pt)
PL (3) PL2646031T3 (pt)
PT (3) PT3884947T (pt)
RS (3) RS65198B1 (pt)
RU (1) RU2640561C2 (pt)
SI (2) SI3222280T1 (pt)
TW (1) TWI618536B (pt)
WO (1) WO2012075459A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP2135603B1 (en) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
TWI618536B (zh) * 2010-12-03 2018-03-21 歐瑞根治療有限公司 於納曲酮療法中增加藥物生物可利用性
WO2013184837A1 (en) 2012-06-06 2013-12-12 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US20180015042A1 (en) * 2015-02-07 2018-01-18 Intas Pharmaceuticals Ltd. Pharmaceutical composition for the treatment of obesity
US20200101066A1 (en) * 2017-03-28 2020-04-02 LDN Pharma Limited Agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2007016108A1 (en) 2005-07-27 2007-02-08 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2135603B1 (en) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
EP1954316A1 (en) 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK2526932T3 (en) * 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
KR101264789B1 (ko) * 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
CA2693992C (en) * 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
TWI609702B (zh) * 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
KR20180066272A (ko) 2006-11-09 2018-06-18 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
EP2139485B1 (en) * 2007-04-11 2012-10-17 BioMarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
TWI618536B (zh) * 2010-12-03 2018-03-21 歐瑞根治療有限公司 於納曲酮療法中增加藥物生物可利用性

Also Published As

Publication number Publication date
SI2646031T1 (sl) 2017-07-31
EP4349369A2 (en) 2024-04-10
PT3222280T (pt) 2021-04-22
ES2866879T3 (es) 2021-10-20
CA2819262C (en) 2024-05-28
CY1118968T1 (el) 2018-01-10
EP3222280B1 (en) 2021-01-20
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
HUE053831T2 (hu) 2021-07-28
KR20140035320A (ko) 2014-03-21
RS65198B1 (sr) 2024-03-29
CA3239386A1 (en) 2012-06-07
KR101984500B1 (ko) 2019-05-31
EP2646031A1 (en) 2013-10-09
HUE034393T2 (en) 2018-02-28
HRP20210618T1 (hr) 2021-09-17
EP3884947B1 (en) 2023-11-15
DK3222280T3 (da) 2021-04-19
KR20200044158A (ko) 2020-04-28
CA2819262A1 (en) 2012-06-07
LT2646031T (lt) 2017-06-26
IL270841A (en) 2020-01-30
SI3222280T1 (sl) 2021-11-30
ES2625527T3 (es) 2017-07-19
JP2024071605A (ja) 2024-05-24
KR20180069089A (ko) 2018-06-22
JP2013544290A (ja) 2013-12-12
RU2017144631A (ru) 2019-02-18
CL2013001564A1 (es) 2014-05-02
ES2625527T9 (es) 2018-09-25
JP2016210809A (ja) 2016-12-15
EP2646031A4 (en) 2014-04-23
HRP20170734T1 (hr) 2017-08-11
PT3884947T (pt) 2024-02-16
CN103313711A (zh) 2013-09-18
PL3884947T3 (pl) 2024-05-06
JP6008866B2 (ja) 2016-10-19
JP2019056004A (ja) 2019-04-11
RU2640561C2 (ru) 2018-01-09
PT2646031T (pt) 2017-05-25
IL279626A (en) 2021-03-01
EP2646031B9 (en) 2018-01-10
AR093182A1 (es) 2015-05-27
MX2013006071A (es) 2013-10-01
AU2011336304B2 (en) 2017-03-30
EP3884947A1 (en) 2021-09-29
FI3884947T3 (fi) 2024-01-30
AU2011336304A1 (en) 2013-07-11
RU2013127423A (ru) 2015-01-10
AR124500A2 (es) 2023-04-05
LT3222280T (lt) 2021-05-10
KR20190058702A (ko) 2019-05-29
AU2017204309A1 (en) 2017-07-13
HRP20240115T1 (hr) 2024-06-07
PL3222280T3 (pl) 2021-11-29
TW201304780A (zh) 2013-02-01
JP2022060331A (ja) 2022-04-14
RU2017144631A3 (pt) 2021-04-13
EP4349369A3 (en) 2024-05-15
IL226504B (en) 2021-01-31
US20130245056A1 (en) 2013-09-19
TWI618536B (zh) 2018-03-21
KR20210063473A (ko) 2021-06-01
CY1124331T1 (el) 2022-07-22
WO2012075459A1 (en) 2012-06-07
EP3222280A1 (en) 2017-09-27
JP6456890B2 (ja) 2019-01-23
RS62149B1 (sr) 2021-08-31
JP7025319B2 (ja) 2022-02-24
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
KR102105857B1 (ko) 2020-05-04
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
DK2646031T3 (en) 2017-05-22
LT3884947T (lt) 2024-03-12
MX356801B (es) 2018-06-13

Similar Documents

Publication Publication Date Title
FR18C1043I2 (fr) Therapie antivirale
IL279626A (en) Increasing the bioavailability of a drug in treatment with naltrexone
SMT201500232B (it) Dispositivo per la somministrazione de farmaci
IL226245A0 (en) History
HK1208186A1 (en) Drug protein conjugates
HK1205156A1 (en) Cyclodextrin-based polymers for therapeutic delivery
HK1208187A1 (en) Drug protein conjugates
EP2560624A4 (en) THERAPEUTIC FORMULATION TO REDUCE THE SIDE EFFECTS OF MEDICATION
DK2652652T3 (da) Medikmentadministration
GB201017597D0 (en) Drug detection
BR112013008074A2 (pt) combinações farmacêuticas
AP2015008208A0 (en) Pharmaceutical administration forms comprising
BRPI0922888A2 (pt) administração combinada de fármaco
EP2898912A4 (en) INSTRUMENT FOR MEDICINE ADMINISTRATION
HK1204962A1 (en) Cyclodextrin-based polymers for therapeutic delivery
EP2564852A4 (en) MEDICAMENT TREATING CEREBRAL TUMORS
FR2967672B1 (fr) Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
HRP20141173T1 (hr) Medikament koji sadrži miramistin
EP2548580A4 (en) PHARMACEUTICAL FOR PSEUDOTRAINING THERAPY
GB201019527D0 (en) Redox drug derivatives
GB201006112D0 (en) Redox drug derivatives
FI20100366A0 (fi) Järjestelmä lääkityksen noudattamiseksi
ZA201201424B (en) Pharmaceutical dosage form

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL